8th February 2016 Content supplied by: MarketResearchReports.biz
EpiCast Report: RSV Infection - Epidemiology Forecast to 2024
This is an EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
In each of the 7 major markets (US, France, Germany, Italy, Spain, UK, and Japan), GlobalData epidemiologists determined that the prophylactic RSV population in 2014, which includes the preterm infant (less than 37 weeks gestational age) population that survived to 2 years of age, the population of infants with neonatal chronic lung disease (CLD), the population of children with congenital respiratory or neuromuscular diseases that compromise respiratory function, the population of children with hemodynamically significant congenital heart disease, and the population of third-trimester pregnant women, was highest for the US, followed by the 5EU (France, Germany, Italy, Spain, and UK) and Japan. This trend was also seen in the hospitalized RSV population, where the US had the highest number of confirmed and estimated RSV hospitalized cases in 2014, followed by the 5EU and Japan.
The RSV EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RSV market.
- Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for RSV prophylactics and therapeutics in each of the markets covered.
Download Detail Report With Complete Table of Contents at: http://www.marketresearchreports.biz/sample/sample/556455
Date Published: 8th February 2016
Source article link: View
PROMILITE M4® - Rapid ATP
Collaboration Expands ELITe InGenius™ Menu